Flow Diversion Aneurysm Treatment - Global Strategic Business Report

The global market for Flow Diversion Aneurysm Treatment was estimated at US$5.3 Billion in 2024 and is projected to reach US$8.2 Billion by 2030, growing at a CAGR of 7.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Flow Diversion Aneurysm Treatment market.

Global Flow Diversion in Aneurysm Treatment - Key Trends & Drivers Summarized

Why Is Flow Diversion Transforming the Management of Intracranial Aneurysms?

Flow diversion has emerged as a breakthrough technique in the treatment of intracranial aneurysms, particularly for wide-neck, large, fusiform, and previously untreatable aneurysms that pose challenges for conventional clipping or coiling methods. Unlike traditional endovascular coiling that fills the aneurysm sac directly, flow diverters are stent-like devices implanted within the parent artery to redirect blood flow away from the aneurysm. This promotes intra-aneurysmal thrombosis and vascular remodeling, leading to gradual occlusion and long-term stabilization of the aneurysm wall.

The minimally invasive nature of this approach, combined with its efficacy in complex and unruptured aneurysms, has positioned flow diversion as a preferred strategy in neurointervention. Clinical adoption has surged in response to increasing awareness of its favorable long-term outcomes, reduced retreatment rates, and applicability to challenging anatomical regions such as the internal carotid artery. As neurological imaging and intervention capabilities evolve, flow diversion is being integrated into early-stage treatment planning, especially for aneurysms previously considered inoperable.

What Innovations Are Enhancing the Efficacy and Safety of Flow Diverters?

Technological advancements in flow diverter design and delivery systems are playing a critical role in improving procedural outcomes and safety profiles. The latest generation of flow diverters features lower-profile systems compatible with smaller microcatheters, allowing for better navigability through tortuous intracranial vasculature. Innovations such as resheathable and repositionable devices give neurointerventionists greater control during deployment, reducing the risk of malposition or vessel injury.

Surface modifications and anti-thrombotic coatings such as phosphorylcholine or hydrophilic polymer coatings are being adopted to enhance hemocompatibility and reduce reliance on long-term dual antiplatelet therapy. Some next-gen flow diverters are even bioresorbable, designed to degrade once vascular remodeling is achieved, minimizing long-term implant risks. Additionally, imaging-guided navigation systems, including 3D rotational angiography and roadmap fluoroscopy, are improving the precision and confidence of device placement. These innovations are enabling treatment of aneurysms in previously inaccessible or high-risk locations, including distal vessels and bifurcation points.

Which Patient Populations and Clinical Settings Are Driving Demand for Flow Diversion?

Flow diversion is most commonly employed for unruptured intracranial aneurysms in adult patients, particularly in the anterior circulation (e.g., internal carotid artery). However, growing clinical evidence is expanding its use in posterior circulation aneurysms, recurrent aneurysms post-coiling, and selected cases of ruptured aneurysms under compassionate use or advanced center protocols. The approach is especially beneficial for patients with large or giant aneurysms, where coiling would be less effective or technically challenging.

Tertiary and quaternary care centers equipped with specialized neurointerventional capabilities are the primary sites of adoption, although the technique is gradually being disseminated to regional and community hospitals as training and device availability improve. Increased detection of asymptomatic aneurysms through incidental brain imaging is also contributing to earlier intervention using flow diversion. Meanwhile, aging populations and increasing stroke awareness are expanding the eligible patient base, as early identification and elective treatment of aneurysms gain clinical traction.

What Are the Primary Drivers Supporting Growth in the Flow Diversion Market?

The growth in the flow diversion aneurysm treatment market is driven by several key factors related to procedural efficacy, clinical demand, and product innovation. A major driver is the expanding body of real-world evidence and long-term follow-up data demonstrating high occlusion rates, low retreatment needs, and favorable neurological outcomes. As neurointervention shifts toward minimally invasive solutions with durable results, flow diversion aligns well with both clinician and patient expectations.

In parallel, improvements in device flexibility, deliverability, and safety features are broadening the anatomical range and complexity of aneurysms that can be treated with flow diversion. Rising investments in stroke and neurovascular intervention infrastructure particularly in emerging economies are also facilitating broader access to advanced aneurysm therapies. Moreover, continuous training, proctoring, and certification programs by device manufacturers and academic centers are accelerating clinical adoption. Together, these drivers are reinforcing flow diversion as a cornerstone technique in the next-generation management of cerebral aneurysms.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Flow-Diverting Stents segment, which is expected to reach US$5.4 Billion by 2030 with a CAGR of a 6.4%. The Intrasaccular Flow Disruption Devices segment is also set to grow at 10.5% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $1.4 Billion in 2024, and China, forecasted to grow at an impressive 7.6% CAGR to reach $1.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Flow Diversion Aneurysm Treatment Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Flow Diversion Aneurysm Treatment Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Flow Diversion Aneurysm Treatment Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Acandis GmbH, BALT Group, Cardinal Health Inc., Endologix LLC, and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 42 companies featured in this Flow Diversion Aneurysm Treatment market report include:

• Acandis GmbH
• BALT Group
• Cardinal Health Inc.
• Endologix LLC
• Evasc Medical Systems Corp.
• Imperative Care Inc.
• InspireMD Inc.
• Johnson & Johnson Services Inc.
• Kaneka Corporation
• Lepu Medical Technology Co. Ltd.
• Medtronic Plc
• Merlin MD Pte. Ltd.
• MicroPort Scientific Corporation
• MicroVention Inc. (Terumo)
• Mizuho Medical Co., Ltd.
• Oxford Endovascular Ltd.
• Penumbra Inc.
• Phenox GmbH
• Rapid Medical Ltd.
• Sequent Medical Inc.
• Siemens AG
• Stryker Corporation
• Terumo Corporation
• Wallaby Medical LLC
• W.L. Gore & Associates, Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.